The state of North Carolina currently has 30 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
Recruiting
This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Post Acute Sequelae Covid-19 Hyposmia
Strategies and Treatments for Respiratory Infections &; Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622, an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of S-217622 when given in addition to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Duke University Hospital (Site 301-006), Durham, North Carolina +1 locations
Conditions: COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Recruiting
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Atea Study Site, Chapel Hill, North Carolina
Conditions: SARS CoV 2 Infection, COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: COVID-19
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. Substudy A design: Phase 1 includes participant... Read More
Gender:
All
Ages:
Between 6 months and 11 years
Trial Updated:
03/12/2024
Locations: Atrium Health - Carolinas Medical Center, Charlotte, North Carolina +1 locations
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: 338 - Carolina Internal Medicine Associates, Asheville, North Carolina +1 locations
Conditions: COVID-19
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Duke University Hospital (Site 301-006), Durham, North Carolina +1 locations
Conditions: COVID-19
T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19
Recruiting
T-Cell Mitochondrial Respiration Response to Ketone monoester (Ketoneaid) in Healthy Volunteers and COVID-19
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Christina Barkauskas, Durham, North Carolina
Conditions: COVID-19 Acute Respiratory Distress Syndrome
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Recruiting
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Infectious Pneumonia, Severe COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/25/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Recruiting
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. Participants will self-report any new or worsening symptoms or medical events experienced while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a partic... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
02/12/2024
Locations: Vaidya MD PLLC, Clayton, North Carolina +6 locations
Conditions: Covid19
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
Recruiting
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question[s] and goals of this study are: does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit? does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit? considering recent national changes to funding and av... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: COVID-19